The University of Chicago Header Logo

Connection

Elaine M. Worcester to Crystallization

Back to Details
This is a "connection" page, showing publications Elaine M. Worcester has written about Crystallization.
Elaine M. Worcester
Connection Strength
0.876
Crystallization
  1. Evidence for disordered acid-base handling in calcium stone-forming patients. Am J Physiol Renal Physiol. 2020 02 01; 318(2):F363-F374.
    View in: PubMed
    Score: 0.173
  2. Pathophysiology-based treatment of idiopathic calcium kidney stones. Clin J Am Soc Nephrol. 2011 Aug; 6(8):2083-92.
    View in: PubMed
    Score: 0.097
  3. Renal intratubular crystals and hyaluronan staining occur in stone formers with bypass surgery but not with idiopathic calcium oxalate stones. Anat Rec (Hoboken). 2008 Mar; 291(3):325-34.
    View in: PubMed
    Score: 0.076
  4. Pathophysiological correlates of two unique renal tubule lesions in rats with intestinal resection. Am J Physiol Renal Physiol. 2006 Nov; 291(5):F1061-9.
    View in: PubMed
    Score: 0.070
  5. Renal crystal deposits and histopathology in patients with cystine stones. Kidney Int. 2006 Jun; 69(12):2227-35.
    View in: PubMed
    Score: 0.068
  6. Stones from bowel disease. Endocrinol Metab Clin North Am. 2002 Dec; 31(4):979-99.
    View in: PubMed
    Score: 0.053
  7. What can the microstructure of stones tell us? Urolithiasis. 2017 Feb; 45(1):19-25.
    View in: PubMed
    Score: 0.035
  8. Inhibitors of stone formation. Semin Nephrol. 1996 Sep; 16(5):474-86.
    View in: PubMed
    Score: 0.034
  9. Formation of hydrated calcium oxalates in the presence of poly-L-aspartic acid. Scanning Microsc. 1996; 10(2):415-23; 423-4.
    View in: PubMed
    Score: 0.033
  10. Osteopontin production by cultured kidney cells. Ann N Y Acad Sci. 1995 Apr 21; 760:266-78.
    View in: PubMed
    Score: 0.031
  11. Osteopontin inhibits nucleation of calcium oxalate crystals. Ann N Y Acad Sci. 1995 Apr 21; 760:375-7.
    View in: PubMed
    Score: 0.031
  12. Urinary calcium oxalate crystal growth inhibitors. J Am Soc Nephrol. 1994 Nov; 5(5 Suppl 1):S46-53.
    View in: PubMed
    Score: 0.030
  13. The effect of warfarin on urine calcium oxalate crystal growth inhibition and urinary excretion of calcium and nephrocalcin. Calcif Tissue Int. 1993 Oct; 53(4):242-8.
    View in: PubMed
    Score: 0.028
  14. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res. 1992 Sep; 7(9):1029-36.
    View in: PubMed
    Score: 0.026
  15. Comparison of the pathology of interstitial plaque in human ICSF stone patients to NHERF-1 and THP-null mice. Urol Res. 2010 Dec; 38(6):439-52.
    View in: PubMed
    Score: 0.023
  16. Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int. 2007 Dec; 72(12):1503-11.
    View in: PubMed
    Score: 0.019
  17. Crystal-associated nephropathy in patients with brushite nephrolithiasis. Kidney Int. 2005 Feb; 67(2):576-91.
    View in: PubMed
    Score: 0.015
  18. Effects of urinary macromolecules on hydroxyapatite crystal formation. J Am Soc Nephrol. 2001 Oct; 12(10):2108-2116.
    View in: PubMed
    Score: 0.012
  19. Role of anionic proteins in kidney stone formation: interaction between model anionic polypeptides and calcium oxalate crystals. J Urol. 2000 Apr; 163(4):1343-8.
    View in: PubMed
    Score: 0.011
  20. Control of calcium oxalate crystal structure and cell adherence by urinary macromolecules. Kidney Int. 1998 Apr; 53(4):952-7.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.